arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

COMPUGEN LTD

CGEN
$2.40 ▲ +0.09 (+3.90%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
92
Health
Excellent
Bullish
auto_awesome

Analytical Summary

COMPUGEN LTD shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $224.2M
Dividend Yield
Revenue Growth 161.1%
Op. Margin 43.1%
ROIC 30.4%
FCF / Share $0.34
Trailing P/E 6.3x
Price / Book 2.2x
FCF Yield 14.0%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$72.76M
↑ +161.1%
Net Income Profit after all expenses
$35.34M
↑ +348.4%
Operating Margin Operating profit as % of sales
43.1%
↑ +180.6% 95th
FCF / Share Free cash flow per share
$0.34
↓ -39.3%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
97
Returns
94
Financial Health
99
Cash Quality
60

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 18 quarters